DSIP vs Melatonin: What the Sleep Evidence Shows

DSIP hasn't been shown to work better than melatonin. No published human sleep trial has compared them. The DSIP vs melatonin question also depends on the sleep problem: melatonin's role in sleep timing is much better understood.

For insomnia, meaning persistent trouble falling or staying asleep, DSIP's findings remain small, old and mixed. If melatonin hasn't helped, that doesn't establish DSIP as the next step.

DSIP vs melatonin: what is actually different?

Melatonin is a hormone, a chemical messenger, made mainly by the pineal gland, a small structure in the brain. Its evening rise helps signal nighttime. In the United States, melatonin is sold without a prescription as a dietary supplement. The National Institutes of Health's melatonin guide explains that distinction.

DSIP stands for delta sleep-inducing peptide. It's a chain of nine amino acids, the building blocks of proteins. Schoenenberger and Monnier's 1977 PNAS paper described its isolation from rabbits and brain-wave changes after synthetic DSIP was given to rabbits. Compounded means prepared by a pharmacy for an individual prescription.

A 2006 Journal of Neurochemistry review described missing pieces. Researchers hadn't isolated DSIP's gene, the genetic instructions for making it, or a specific receptor, the receiving point for a cell signal. Those links remain unestablished. Our guide to what DSIP is follows that unresolved biology.

Melatonin for sleep timing is different from treating insomnia

Jet lag shifts the clock. Chronic insomnia involves ongoing difficulty sleeping despite having the chance to sleep. Those problems can feel similar at bedtime while calling for different approaches.

Melatonin has evidence for some timing problems, including jet lag. That doesn't make it a dependable answer for every reason someone lies awake.

The American Academy of Sleep Medicine's 2017 guideline in Journal of Clinical Sleep Medicine states:

We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults.

The recommendation is rated weak, reflecting uncertainty in the evidence. It addresses adult chronic insomnia, rather than every possible use of melatonin. The guideline also places cognitive behavioral therapy for insomnia first: a structured treatment addressing habits and thoughts that keep sleep problems going.

DSIP doesn't fill that evidence gap. In Bes and colleagues' 1992 Neuropsychobiology study, 16 people with chronic insomnia received DSIP or placebo, an inactive comparison. Some sleep-recording measures favored DSIP, but the effects were weak and people didn't rate their sleep as better. The broader DSIP benefits record is similarly mixed.

Can DSIP and melatonin be used together?

There is no established human sleep-study basis for combining them. Different proposed mechanisms don't demonstrate that a combination works better or is safe.

Animal comparisons do exist. A 1984 study in Peptides tested DSIP and melatonin separately and together in rats. It examined changes in body temperature across the daily cycle, including after removal of hormone-producing glands. It wasn't a trial of insomnia treatment in people.

That distinction matters when a combination is described as complementary. A rat's temperature response cannot establish better sleep, a useful combination dose or fewer side effects in a person. Nor does evidence about epitalon and melatonin production answer a DSIP combination question; epitalon is a different peptide.

Better-known doesn't mean free of uncertainty

Melatonin can cause daytime sleepiness, headache, dizziness or nausea. NIH describes short-term use as appearing safe for most people, while long-term safety remains uncertain. Medication interactions matter too.

The contents of a supplement add another variable. In Erland and Saxena's 2017 Journal of Clinical Sleep Medicine analysis, products bought in Canada contained from 83% less to 478% more melatonin than their labels stated. Some also contained serotonin, another chemical messenger.

A newer U.S. survey by Pawar and colleagues, published in Drug Testing and Analysis in 2025, examined 110 products marketed for children. Content ranged from none to 667% of the labeled amount. That sample doesn't represent every adult product, but it shows why a label alone doesn't settle exposure.

For DSIP, the main problem is how much remains unknown. FDA's emideltide review—emideltide is another name for DSIP—found only small, short-term human studies, mostly with the peptide given into a vein. In studies of people going through alcohol or opioid withdrawal, reported side effects included passing headache, nausea and vertigo, a spinning sensation, plus cases of low blood pressure that worsened after a second injection. FDA called DSIP's safety insufficiently characterized; our DSIP side effects guide covers that record. It found no clinical safety data for under-the-skin administration. A prescription doesn't make those research gaps disappear.

Where DSIP's federal review stands

As of October 29, 2026, the day this article was written, the official FDA meeting recording shows the July 24, 2026 votes of FDA's Pharmacy Compounding Advisory Committee on two DSIP ingredient forms. Each received six yes votes, seven no votes and one abstention. Neither was recommended for the 503A bulks list, a federal list of bulk ingredients that pharmacies may use to compound prescriptions under section 503A. Those recommendations were advisory, rather than final agency decisions.

DSIP prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

As of October 29, 2026, the day this article was written, an HHS notice filed October 28 announces a draft enforcement-discretion policy on compounding with certain peptides. DSIP is absent from its six-peptide Appendix A; our HHS peptide policy explainer covers the conditions.

Why growth hormone comes up in sleep comparisons

Deep sleep is also called slow-wave sleep because brain recordings show large, slow waves. Growth hormone release often rises around that stage, as Takahashi and colleagues reported in Journal of Clinical Investigation in 1968.

Sermorelin copies the brain's signal for growth hormone release. That connection explains the interest in sleep; it doesn't establish a sleep benefit. A 2001 study report in Dialogues in Clinical Neuroscience described slightly worse sleep-questionnaire scores during treatment in older adults, with the meaning of that small change uncertain. Our sermorelin for sleep guide examines it.

The compounded formulation is different from an FDA-approved sermorelin product once marketed as Geref and since discontinued. The formulation offered here is not FDA-approved.

What a sleep-focused review can clarify

A useful visit starts with the pattern: difficulty falling asleep, repeated awakenings, or a schedule that puts sleep at the wrong time. As NIH's insomnia diagnosis guide explains, a provider also considers snoring, breathing interruptions, current medicines and alcohol. An evaluation can identify other sleep or medical problems that need attention.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses it. The prescriber sets the actual dose and timing.

The useful outcome of that review is an honest look at the evidence behind each option; signs such as loud snoring or waking up gasping can point to a sleep study first. DSIP's name, melatonin's familiarity and a connection to growth hormone can't supply that answer on their own.